Cargando…

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales:	Tice, Jeffrey A, Mandrik, Olena, Thokala, Praveen, Fotheringham, James, Pearson, Steven D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Perspectives on Value
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391090/ https://www.ncbi.nlm.nih.gov/pubmed/34595943 http://dx.doi.org/10.18553/jmcp.2021.27.10.1495

Ejemplares similares

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)

The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Fazioli, Katherine T., et al.
Publicado: (2020)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: McKenna, Avery, et al.
Publicado: (2023)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA
por: Auguste, Bourne, et al.
Publicado: (2021)

Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage
por: Newman, Terri V, et al.
Publicado: (2021)

168 Victory With Voclosporin: A Case of Complete Remission in Severe Lupus Nephritis
Publicado: (2023)

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Synnott, Patricia G, et al.
Publicado: (2021)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Pandey, Rajshree, et al.
Publicado: (2021)

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis
por: Kale, Ajinath, et al.
Publicado: (2023)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
por: Frieri, Marianne, et al.
Publicado: (2015)

Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
por: Shrestha, Sanjeev, et al.
Publicado: (2021)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Voclosporin: First Approval
por: Heo, Young-A
Publicado: (2021)

25 Efficacy of Voclosporin Across Lupus Nephritis Biopsy Classes: Pooled Data From the AURORA and AURA-LV Trials
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin
por: Abdel-Kahaar, Emaad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qcfkhm9iplgvgp8m3s39jnpe00